Global Irreversible Electroporation Ablators Market Size By Type (Generator, Part), By Application (Liver, Pancreas), By Region, And Segment Forecasts, 2023 to 2032

The Global Irreversible Electroporation (IRE) Ablators Market was valued at USD 430 million in 2023 and is projected to reach USD 985 million by 2031, expanding at a CAGR of 10.8% during the forecast period from 2023 to 2031. IRE ablation, a non-thermal and minimally invasive technique, has gained prominence due to its ability to precisely target soft tissue tumors without damaging surrounding critical structures. The increasing prevalence of cancer, growing preference for minimally invasive procedures, and advancements in ablation technologies are key factors propelling the market forward.

Drivers:

Rising Cancer Incidence Globally:

The growing number of cancer cases worldwide, especially liver, pancreatic, and prostate cancers, is driving the demand for advanced tumor ablation techniques like irreversible electroporation.

Surging Demand for Minimally Invasive Treatments:

Patients and healthcare providers increasingly prefer non-thermal ablation methods due to their minimal side effects, reduced recovery times, and precise targeting capabilities.

Technological Innovations in Ablation Devices:

Advancements such as real-time imaging integration, AI-guided electrode placement, and enhanced energy delivery systems are improving procedural accuracy, thus boosting adoption rates.

Restraints:

High Equipment and Procedure Costs:

The high upfront cost of IRE systems and associated consumables can limit adoption, particularly in low- and middle-income countries.

Limited Clinical Awareness and Availability:

Despite its benefits, awareness of IRE technology is relatively low among clinicians, and its availability is still limited to specialized medical centers in developed regions.

Opportunity:

Expanding Applications Beyond Oncology:

Beyond tumor ablation, IRE is being researched for cardiac arrhythmias and urological disorders, opening new growth avenues.

Emerging Markets Adoption:

Countries in Asia-Pacific and Latin America are investing heavily in healthcare infrastructure and advanced treatment modalities, offering significant growth potential for IRE device manufacturers.

Market by System Type Insights:

The Monopolar IRE Systems segment held the largest share in 2023, attributed to their widespread use in treating large and deep-seated tumors. However, Bipolar Systems are expected to grow at a higher rate due to enhanced control over ablation zones and improved patient safety profiles.

Market by End-Use Insights:

The Hospitals segment dominated the market in 2023, driven by the increasing number of cancer treatment centers equipped with advanced ablation technologies. Specialty Clinics are projected to register robust growth due to the rising trend of outpatient procedures and increasing availability of portable IRE systems.

Market by Regional Insights:

North America led the global IRE ablator market in 2023, thanks to early adoption of innovative medical technologies, a strong presence of key players, and favorable reimbursement policies. Asia-Pacific is anticipated to witness the highest growth rate, supported by rising cancer incidence, improving healthcare infrastructure, and government investments in advanced oncology care.

Competitive Scenario:

Leading players in the Global Irreversible Electroporation Ablators Market include AngioDynamics, Inc., Medtronic plc, Johnson & Johnson (Ethicon), Pulse Biosciences, Inc., BTG International Ltd., and Terumo Corporation. These companies are investing in clinical trials, product development, and strategic partnerships to expand their global footprint.

In 2023, Pulse Biosciences received CE Mark approval for its new-generation IRE platform tailored for precision oncology applications.

AngioDynamics expanded its clinical trial program to explore additional indications for its NanoKnife IRE system in pancreatic and prostate cancers.

Medtronic announced a partnership with a leading academic hospital to develop AI-integrated IRE solutions for complex tumor navigation.

Scope of Work – Global Irreversible Electroporation Ablators Market

Report Metric Details

Market Size (2023) USD 430 million

Projected Market Size (2031) USD 985 million

CAGR (2023–2031) 10.8%

Market Segments System Type (Monopolar, Bipolar), End-Use, Region

Growth Drivers Rising cancer incidence, demand for minimally invasive treatments, technological advancements

Opportunities Application in non-oncology fields, adoption in emerging markets

Key Market Developments:

March 2023: AngioDynamics launched an upgraded NanoKnife system with